Condition

Pulmonary Tuberculosis (2)

Community Acquired Pneumonia (1)

Tuberculosis (1)

Overall Status

Completed (3)

Unknown status (1)

Phase

phase 2 (2)

phase 1 (1)

phase 3 (1)

Sponsor

National University Hospital, Singapore (2)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)

TASK Applied Science (1)

Collaborator

Barcelona Centre for International Health Research (1)

Eduardo Mondlane University (1)

GlaxoSmithKline (1)

Research Center Borstel (1)

Intervention

faropenem (4)

rifampicin (2)

amoxicillin/clavulanic acid (1)

amoxicillin/clavulanic acid 500mg/125mg (1)

amoxycillin/clavulanic acid (1)

cefadroxil (1)

ertapenem (1)

meropenem (1)

rifafour e275 (1)

Study Documents

Link to Pubmed (Final publication) (1)

Intervention Type

drug (4)

Funder Type

Other (3)

Industry (1)

Study Type

Interventional (4)

faropenem

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Pulmonary Tuberculosis Trial in Philippines, Singapore, Uganda (Faropenem, Amoxicillin/clavulanic acid, Cefadroxil)

Completed

Pulmonary Tuberculosis

Faropenem
+3 more

Cavite, Philippines
+5 more

Mar 19, 2020

Pulmonary Tuberculosis Trial in Cape Town (Meropenem, Faropenem, Amoxycillin/clavulanic acid)

Completed

Pulmonary Tuberculosis

Meropenem
+3 more

Cape Town, Western Cape, South Africa

TASK Foundation NPC

Sep 11, 2018

Tuberculosis Trial in Singapore (Faropenem, Amoxicillin/clavulanic acid 500mg/125mg, Rifampicin)

Completed

Tuberculosis

Faropenem
+2 more

Singapore, Singapore

National University Hospital

Apr 3, 2017

Community Acquired Pneumonia Trial in China (Faropenem, Ertapenem)

Unknown status

Community Acquired Pneumonia

Faropenem
Ertapenem

Hefei, Anhui, China
+6 more

Sep 4, 2013